DSP-9632P
/ Sumitomo Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
December 20, 2023
Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?
(PubMed, Expert Opin Pharmacother)
- No abstract available
Journal • CNS Disorders • Movement Disorders • Parkinson's Disease
August 09, 2023
A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease
(clinicaltrials.gov)
- P1 | N=7 | Completed | Sponsor: Sumitomo Pharma Co., Ltd. | Recruiting ➔ Completed | N=20 ➔ 7 | Trial completion date: Sep 2023 ➔ Dec 2022 | Trial primary completion date: Sep 2023 ➔ Nov 2022
Enrollment change • Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease • DRD2
June 28, 2022
A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: Sumitomo Pharma Co., Ltd.
New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease • DRD2
1 to 3
Of
3
Go to page
1